Figure 3.

Percent change cytokine interleukin 6 (IL-6) and log-IL-6 level versus baseline. A, Predicted probability of primary outcome versus change in Log IL-6 level from baseline to day 7. Increase in IL-6 at day 7 predicted >50% of the variance in treatment outcome (R² = 0.53). Treatment with Aviptadil is less likely to be associated with a day 7 increase in IL-6 and is associated with higher probability of primary end point (P < 0.001). B, Percent change from pretreatment in group cytokine IL-6 level. A significant difference is seen overall on mixed-model repeated measure between days 3 and 7 favoring Aviptadil (P = 0.024) with independent significance on days 3 (P = 0.002) and 7 (P = 0.06).